Status:
COMPLETED
Protect and Improve Cluster of Differentiation 4 (CD4) Cells and B Cells Lymphocytes
Lead Sponsor:
Trieu, Nguyen Thi, M.D.
Conditions:
HIV-1-infection
AIDS
Eligibility:
All Genders
18-60 years
Phase:
PHASE4
Brief Summary
This is a plant-based medication used to increase the amount, protect, and reduce HIV's impact on T and B lymphocytes.
Detailed Description
Dioscorea cirrhosa, impatiens balsamina, eclipta prostrata, phyllanthus urinaria, adenosma glutinosum, and ascorbic acid are used to elevate T and B lymphocytes level, protect their cells membrane, de...
Eligibility Criteria
Inclusion
- Participants have a decline in CD4 + T-lymphocytes is the hallmark of HIV-1 infection.
- Characterized by rapid loss of resistance: AIDS
- Dermatitis, mouth ulcers, skin rash, itching, weight loss
- HCV (+), HBV (+), Tuberculosis (+)
Exclusion
- Cancer under all form
Key Trial Info
Start Date :
December 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 10 2021
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04770701
Start Date
December 1 2015
End Date
January 10 2021
Last Update
October 17 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Saigon Biopharma LLC
Wilmington, Delaware, United States, 19801-6601
2
Saigon Biopharma Company Limited
Ho Chi Minh City, Vietnam, 700000